JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M002832200 on May 16, 2000

J. Biol. Chem., Vol. 275, Issue 30, 22650-22656, July 28, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/30/22650    most recent
M002832200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pirone, D. M.
Right arrow Articles by Burbelo, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirone, D. M.
Right arrow Articles by Burbelo, P. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

SPECs, Small Binding Proteins for Cdc42*

Dana M. PironeDagger , Shigetomo Fukuhara§, J. Silvio Gutkind§, and Peter D. BurbeloDagger

From the Dagger  Lombardi Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, D. C. 20007 and § Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892

Received for publication, April 4, 2000, and in revised form, May 15, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Rho GTPase, Cdc42, regulates a wide variety of cellular activities including actin polymerization, focal complex assembly, and kinase signaling. We have identified a new family of very small Cdc42-binding proteins, designated SPECs (for Small Protein Effector of Cdc42), that modulates these regulatory activities. The two human members, SPEC1 and SPEC2, encode proteins of 79 and 84 amino acids, respectively. Both contain a conserved N-terminal region and a centrally located CRIB (Cdc42/Rac Interactive Binding) domain. Using a yeast two-hybrid system, we found that both SPECs interact strongly with Cdc42, weakly with Rac1, and not at all with RhoA. Transfection analysis revealed that SPEC1 inhibited Cdc42-induced c-Jun N-terminal kinase (JNK) activation in COS1 cells in a manner that required an intact CRIB domain. Immunofluorescence experiments in NIH-3T3 fibroblasts demonstrated that both SPEC1 and SPEC2 showed a cortical localization and induced the formation of cell surface membrane blebs, which was not dependent on Cdc42 activity. Cotransfection experiments demonstrated that SPEC1 altered Cdc42-induced cell shape changes both in COS1 cells and in NIH-3T3 fibroblasts and that this alteration required an intact CRIB domain. These results suggest that SPECs act as novel scaffold molecules to coordinate and/or mediate Cdc42 signaling activities.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Rho GTPase, Cdc42, regulates numerous and diverse biological activities at both the biochemical and cellular levels. Cdc42 influences membrane trafficking (1), cytokinesis (2), and kinase signaling pathways, leading to transcriptional activation (3). Cdc42 is best known for controlling the formation of filopodia, thin actin-containing structures that protrude from the cell surface (4, 5). In addition to the direct effect of Cdc42 on filopodia formation, Cdc42 can also induce cross-activation of Rac, leading to membrane ruffling (5). This cross-talk among small GTPases may function to coordinate the formation and dismantling of different cortical actin structures, such as filopodia, ruffles, lamellopodia, and membrane blebs, often seen during cell migration (6).

The ability of Cdc42 to influence these diverse activities stems from its interactions with a large number of different kinase and non-kinase effector proteins. Although GTP-bound Cdc42 usually interacts with downstream effector proteins containing the conserved binding motif called a CRIB1 domain (7), some downstream Cdc42 effector proteins such as IQGAP do not contain CRIB domains (8, 9). To date, six distinct families of CRIB domain-containing Cdc42 effector proteins have been identified: PAK (10, 11), MRCK (12), ACK (13), MLK (7, 14), WASP (15, 16) and MSE55/BORG/CEP (17, 18). The first four of these families are kinases. The most extensively studied Cdc42 effector proteins, the PAK kinases (3), participate in the Cdc42-mediated cytoskeleton rearrangements that lead to cell motility (19). PAK kinases also activate the JNK and p38 stress kinase pathways (20-22) and are targets of caspase-mediated proteolytic cleavage during apoptosis (23). MRCK kinases affect actin/myosin reorganization by phosphorylating non-muscle myosin light chain (12). Less is known about the signaling pathways and cellular processes affected by ACK tyrosine kinases, but they may influence cell adhesion signals (24). The fourth family, MLK kinases, play a role in kinesin function and JNK activation (14, 25, 26).

WASP and a related protein, N-WASP, comprise a family of non-kinase CRIB-containing proteins that function in actin polymerization (15, 16). N-WASP regulates filopodia formation by producing free actin filaments either via its cofilin actin-severing domain (16) or through interactions with the actin-severing protein, profilin (27). Both WASP and N-WASP also positively regulate the ARP2/3 protein complex, which stimulates actin nucleation (28, 29). The other non-kinase, CRIB-containing set of Cdc42 effector proteins, is the MSE55/CEP/BORG family, which is the most structurally diverse. This family, consisting of five members, all induce long actin-containing cellular extensions in NIH-3T3 fibroblasts (17, 18).

With so many different Cdc42 effector proteins, many of which may coexist in a single cell, competition and/or some mechanism for coordination must exist to ensure that the proper Cdc42 signal is propagated. Although many individual Cdc42 effector proteins have been studied, little is known about how these effector proteins cooperate and/or compete with each other, either in regulating the cytoskeleton or in kinase signaling. Here, we have identified a novel family of Cdc42 effector proteins that may play a role in this higher level of coordination. This new family, designated SPEC (for Small Protein Effector of Cdc42) has two human members, SPEC1 and SPEC2. Both are very small and are highly conserved. SPECs appear to have multifaceted activities, of which some are independent of Cdc42 binding and some are dependent on Cdc42 binding. For instance, expression of SPECs in NIH-3T3 fibroblasts induced membrane blebbing. SPEC-induced blebbing did not require Cdc42 activity because blebbing still occurred with a CRIB domain mutant of SPEC or in the presence of dominant negative Cdc42. SPEC1 blocked both Cdc42-induced JNK activity and altered Cdc42-induced morphology changes in COS1 cells and in NIH-3T3 fibroblasts in a manner that required an intact CRIB domain and, thus, was dependent on Cdc42 binding. Together these results suggest that SPECs act as novel scaffold molecules to coordinate and/or mediate Cdc42 signaling activities.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification and Cloning of SPECs-- Clones of SPEC1 were identified from a TBLASTN search of the expressed sequence tag (EST) data base at the National Center for Biotechnology Information (NCBI) using the 16-amino acid CRIB core sequence of MSE55 (7) (ISHPLGDFRHTMHVGR) as a query. Several of these human EST clones were obtained from the I.M.A.G.E. consortium (clone ID numbers: 257442, 139233, 160147) and sequenced on an Applied Biosystem 377 DNA sequencer. The GenBankTM accession number of SPEC1 is AF187845. Furthermore, EST clones for human and mouse SPEC1 are quite abundant and are represented by the NCBI Unigene identifiers Hs.22065 and Mm.28189, respectively.

Additional TBLASTN searches of the non-redundant nucleotide data base using the amino acid sequence of SPEC1 as query identified three well separated DNA sequences that if transcribed as a single mRNA and properly spliced might encode a second SPEC-like protein. Two adapter-primers, 5'-GAGGGATCCAGTGAATTCTGGTTGTGT-3' and 5'-GAGCTCGAGCTATCCCGCCTTCGTATC-3', derived from these genomic sequences and corresponding to each end of the putative coding sequence, were synthesized. These two primers were used in reverse transcription-PCR with MCF-7 breast cancer cell RNA as template. After PCR, an approximately 250-base pair PCR fragment was obtained, cut with BamHI/XhoI, and subcloned into the BamHI-XhoI site of pCAF2, a mammalian expression vector (17). DNA sequencing revealed that the nucleotide sequence of this PCR product was, as expected, derived from the three different 5q31 genomic fragments and encodes a protein, designated SPEC2, that was quite similar to SPEC1. SPEC2 has GenBankTM accession number AF189692.

Yeast Two-hybrid Assays-- The yeast two-hybrid assay was performed in the Y190 yeast strain using the pYTH GAL4 DNA binding domain yeast vector and pACT-II GAL4 activation domain yeast vectors (30). cDNAs for SPEC1 (amino acids 2-79) or SPEC2 (amino acids 2-84) were subcloned downstream of the GAL4 DNA binding domain in pYTH-9, and integrated strains were generated as described (30). Deletion mutants of SPEC1 consisting of amino acids 2-27 (SPEC1-del1) or amino acids 48-79 (SPEC1-del2) were constructed in the same way. Wild type and activated mutants of Cdc42, Rac, and Rho were subcloned downstream of the GAL4 activation domain in pACT-II. Protein-protein interactions were detected by assaying for beta -galactosidase activity in a filter assay or by growth on nutrient agar plates lacking histidine (30).

Mammalian Expression Vectors for SPEC1, SPEC2, and Mutants-- The coding sequence of SPEC1 was amplified by PCR from the I.M.A.G.E. cDNA clone (ID 22978) using the two primers 5'-GAGGGATCCAGTGAATTTTGGCACAAAC-3' and 5'-GAGCTCGAGCTATAAGCCCCTAGAATTG-3'. This PCR product was then subcloned in-frame into the BamHI-XhoI sites downstream of an N-terminal myc epitope-tagged pcDNA-III (Invitrogen) or an N-terminal FLAG epitope-tagged pCAF2 mammalian expression vector. An additional C-terminal myc epitope-tagged SPEC1 construct was constructed in the pcDNA-III mammalian expression vector. Untagged SPEC1 constructs were also constructed using the bicistronic enhanced green fluorescent protein (EGFP) vector (CLONTECH). The integrity of all constructs was confirmed by DNA sequencing.

Several SPEC1 mutant constructs were generated from the epitope-tagged constructs by using SPEC1 sequence-specific oligonucleotides and the QuickChange mutagenesis kit (Stratagene). Four single or multiple SPEC1 point mutants containing alanine substitutions in the N terminus (SPEC1-C10A,C11A), the CRIB domain (SPEC1-H38A and SPEC1-P35A,H38A,H41A) or in the C terminus (SPEC1-Q62A,K64A) were constructed. The integrity of all constructs was confirmed by DNA sequencing. All of these mutants and their parent constructs had approximately similar levels of expression in transfected cells as judged by immunofluorescence.

JNK Kinase Assays-- COS1 cells were used to examine whether SPEC influenced JNK kinase activation using ATF-2 as substrate as described (31). Equal amounts of DNA were used in each transfection.

Immunofluorescence-- Immunofluorescence of NIH-3T3 fibroblasts was performed essentially as described (17) except that LipofectAMINE Plus (Life Technologies, Inc.) was used as the transfection reagent. Twenty-four hours post-transfection, NIH-3T3 fibroblasts were fixed and permeabilized on glass coverslips coated with polylysine. Coverslips were stained with the myc and FLAG anti-epitope primary antibodies including mouse anti-FLAGTM M2 (Sigma), mouse anti-c-myc monoclonal antibody (Sigma), and polyclonal anti-FLAGTM/Octaprobe antibody (Santa Cruz Biotechnology). Fluorescein-conjugated goat anti-mouse IgG (Rockland Immunochemicals, Gilbertsville, PA), Texas Red anti-mouse (Jackson ImmunoResearch Laboratories, Inc.), and FITC-conjugated goat-anti-rabbit (Rockland Immunochemicals) were used as secondary antibodies. Texas Red-conjugated Phalloidin (Sigma) was used to stain F-actin. Nuclear and phosphotidylserine staining was also performed using 4,6-diamidino-2-phenylindole (Sigma) and annexin-V (Trevigen, Inc.), respectively.

Blebbing cells were quantified in vector alone and in SPEC-ransfected cells 24 h post-ransfection. Cells with two or more outpouchings were scored as positive for membrane blebbing. Fifty to one hundred cells were scored from each of at least three independent transfections. A Zeiss Photomicroscope III equipped with a Planapo 63X/1.4 NA phase 3 objective was used, and photographs were taken with Kodak TMAX400 film using a Nikon N6006 camera.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of Genes for SPEC1 and SPEC2-- Most known Cdc42-inding proteins contain a conserved core domain, the CRIB domain (7). We looked for additional proteins that might bind Cdc42 by searching the human EST data base for sequences similar to the CRIB domain of the non-kinase Cdc42 effector protein MSE55/CEP1 (17) and identified many cDNAs encoding the same small protein. The DNA sequences of several independent human clones comprising a contig spanning 1.8 kilobases each showed an open reading frame of 79 amino acid residues, which we designated SPEC1 (Fig. 1). These cDNAs encoding the SPEC1 protein contained a Kozak consensus sequence and an upstream in-frame stop codon and did not encode any proteins longer than SPEC1. A second human SPEC family member, designated SPEC2, was identified by searching the non-redundant GenBankTM data base. This search identified three short separated genomic regions from chromosome 5q31, spanning at least 28 kilobases (GenBankTM accession numbers AC001489 and AC001223) that if transcribed and properly spliced would encode a second SPEC-like protein. To clone the SPEC2 cDNA sequence, primers were designed for the two extreme ends of the genomic regions and used in reverse transcription-PCR. This approach yielded a 250-base pair PCR fragment containing an open reading frame of 84 amino acids (Fig. 1). Comparison of this sequence with 5q31 genomic sequences confirmed that the full-length SPEC2 protein was encoded in three exons spanning at least 28 kilobases.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 1.   The SPEC protein family. Alignment of full-length human SPEC1 and SPEC2 amino acid sequences. ESTs corresponding to mouse SPEC1 (AI472516), chicken SPEC1 (AI981286), and Xenopus SPEC2 (AW644132) and Drosophila SPEC2 (AAF51990) are also shown. Vertical lines identify identical residues, colons represent conservative substitutions, and the numbers at the ends represent the total number of amino acid residues. The CRIB consensus is shown (7), and sequences matching this consensus sequence are shown in bold letters. Human SPEC1 and SPEC2 sequences are available from GenBankTM under accession numbers AF187845 and AF189692, respectively.

In addition to the human SPEC1 and SPEC2 proteins, we have also identified both SPEC1 and SPEC2 homologs in other organisms. We have identified SPEC1 homologs from mouse (GenBankTM AI472516) and chicken (GenBankTM AI981286) that are 96 and 83% identical to SPEC1 at the amino acid level, respectively (Fig. 1). We have also identified SPEC2 homologs from mouse (GenBankTM AW061198), rat (GenBankTM AA944330), Drosophila (AA820736), and ascidian (Halocynthia roretzi; GenBankTM AV382466) (Fig. 1). Identification of the SPEC proteins in such diverse organisms suggests their function may be conserved through evolution.

SPECs Represent a Novel Family of Cdc42-binding Proteins-- SPEC1 and SPEC2 represent two members of a new protein family that are 76% similar over their entire length (Fig. 1) and encode proteins with predicted molecular masses of 7.9 kDa and 8.4 kDa, respectively. Both SPECs contain a highly conserved N-terminal region and a typical CRIB domain. The CRIB domains of the SPECs extend beyond the CRIB core sequence and contain the consensus sequence DR(S/T)MIGEPXNFVHXXHAGSGD/EAXXG, where A represents an aliphatic amino acid, and bold letters identify the CRIB core (Fig. 1). In the C terminus of both proteins there is a relatively small conserved sequence containing the nine-amino acid consensus sequence, (V/I)Q(E/N)QM(R/Q)SKG (Fig. 1). This region may be part of an extended high affinity Cdc42 binding site (32, 33).

CRIB-dependent Cdc42 Binding by SPECs-- Since proteins containing a consensus CRIB domain will bind Cdc42 and/or Rac (7), we predicted that both SPEC1 and SPEC2 also would interact with Cdc42 and/or Rac. We tested this prediction in a yeast two-hybrid system. Both SPEC1 and SPEC2 interacted strongly with a constitutively activated mutant of Cdc42 (Cdc42-Q61L), weakly with an activated mutant of Rac1 (Rac1-Q61L), and not at all with an activated mutant of RhoA (RhoA-Q63L) using both the beta -galactosidase filter assay (Fig. 2) and growth on selective media (data not shown). Although interaction of SPECs with wild type Cdc42 and wild type Rac1 was not observed, our results are consistent with yeast two-hybrid experiments using other CRIB-containing Cdc42 effector proteins, such as WASP (30). Additionally, SPEC CRIB deletion mutants retaining either the N terminus (SPEC1-del1; amino acids 2-27) or the C terminus (SPEC1-del2; amino acids 48-79) were unable to bind to an activated Cdc42 mutant (Fig. 2). Collectively, these results demonstrate that SPECs can interact with Cdc42 in a CRIB-dependent fashion and suggest that SPECs may function normally in Cdc42-dependent signaling.


View larger version (6K):
[in this window]
[in a new window]
 
Fig. 2.   SPEC1 and SPEC2 interact with Cdc42 in yeast two-hybrid assays. pYTH9 GAL4-DNA binding constructs were generated for SPEC2, SPEC1, or deletions of SPEC1 and then integrated into Y190 yeast cells. These yeast strains were used as host cells for transformations with pACT-GAL4 activation constructs to test interactions with Rho GTPases. The strength of the interaction was classified by the time taken for colonies to turn blue in the beta -galactosidase filter assay: +++, <25 min; ++, 25-50 min; +50-100 min; -, no color change by 100 min; and ND, not determined.

SPEC1 Expression Inhibits Cdc42-induced JNK Activity-- Since a variety of studies have shown both that Cdc42 (31, 34) and some Cdc42 effector proteins (14, 20-22, 26) can activate JNK activity, we tested SPEC1 and several SPEC1 mutants for their effect on Cdc42-induced JNK activation. First, an expression construct of human SPEC1 carrying an N-terminal FLAG epitope tag was transfected into NIH-3T3 fibroblasts, and its expression was analyzed by Western blotting using a monoclonal antibody against the N-terminal FLAG epitope tag. Using this approach, SPEC1 was detected in lysates as an ~8 kDa species (data not shown), of which about 1 kilobase is contributed by the epitope tag. Second, several SPEC1 mutants were constructed, including two CRIB mutants and a C-terminal double mutant. The two CRIB mutants, SPEC1-H38A and SPEC1-P33A,H38A,H41A, contain alanine substitutions within critical contact sites known to be involved in Cdc42 binding (33, 34). The third mutant, SPEC1-Q62A,K66A, contained mutations within the nine-amino acid region conserved between both SPEC proteins that might be part of an extended high affinity Cdc42 binding site. COS1 cells were cotransfected with the expression vectors for GFP (control) or Cdc42-Q61L, hemagglutinin (HA) epitope-tagged JNK, and FLAG-tagged SPEC1 constructs. After 24 h, transiently expressed HA-JNK was isolated by immunoprecipitation and used for in vitro kinase assays. All SPEC1 constructs tested were not able to stimulate JNK activity on their own (Fig. 3A). Expression of Cdc42 with HA-JNK stimulated kinase activity (Fig. 3, A and B). Cotransfection of cells with wild-type SPEC1 significantly reduced the Cdc42-induced JNK activation (Fig. 3, A and B). In contrast, SPEC1-P33A,H38A,H41A or SPEC1-Q62A,K66A were markedly less effective at blocking Cdc42-induced JNK activation (Fig. 3, A and B). In addition, a similar failure to block Cdc42-induced JNK activation was also observed with the single CRIB domain mutant (data not shown). Although we cannot rule out the possibility that our overexpression studies have resulted in abnormally high levels of SPEC1, which may nonspecifically inhibit Cdc42 signaling pathways, these results may also suggest that SPEC1 modulates JNK activity by binding or sequestering Cdc42 through a CRIB-dependent interaction.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   SPEC1 inhibits Cdc42-induced JNK activation. COS1 cells were transfected with expression vectors for GFP (control) or activated Cdc42 mutant (Cdc42-QL61), HA-tagged JNK, and different FLAG-tagged SPEC1 constructs. Following immunoprecipitation, JNK activity was assayed using ATF-2 as substrate (A). Similar results were obtained in three independent experiments. This assay was normalized by Western blot analysis using anti-HA immunoprecipitates from the cellular lysates and immunodetected with JNK antisera as described under "Experimental Procedures." Results are the averages ± S.E. of three experiments. WT, wild type.

SPEC1 Expression Inhibits Cdc42-induced Morphological Changes in COS1 Cells-- We next examined the cellular distribution of epitope-tagged SPEC1 expression by immunofluorescence. In COS1 cells, SPEC1 showed diffuse cytoplasmic localization (Fig. 4B). Additionally, SPEC-expressing cells did not show altered actin structures or cell morphology (data not shown). We next determined whether SPEC1 influenced Cdc42 function when co-expressed with Cdc42. COS1 cells expressing the constitutively active Cdc42-Q61L mutant exhibited a widely spread and flattened phenotype with some filopodia (Fig. 4, A and B). Cotransfection of SPEC1 with Cdc42-Q61L resulted in cells that were more elevated and much less spread than cells expressing Cdc42-Q61L alone (compare Fig. 4, C and D with A) or untransfected cells (data not shown). In contrast to what was seen with wild-type SPEC1, cells coexpressing Cdc42-Q61L and the CRIB domain mutant (SPEC1-H38A) resembled cells transfected with Cdc42-Q61L alone (compare Fig. 4, E and F with A). These results suggest that SPEC1 modifies Cdc42 function. In these experiments, SPEC1 appears to alter Cdc42 activity by binding to it via the CRIB domain. These results suggest that SPECs may function to block the interaction of Cdc42 with other effector proteins, although we cannot rule out the possibility that the observed blocking activity was due to overexpression of SPEC1 protein.


View larger version (93K):
[in this window]
[in a new window]
 
Fig. 4.   SPEC1 alters Cdc42 activity in COS1 cells. COS1 cells were transfected with myc-tagged Cdc42-Q61L and processed for indirect immunofluorescence at 24 h post-transfection using monoclonal antibodies specific for the myc epitope tag followed by either Texas Red-conjugated goat anti-mouse antibodies or FITC-conjugated goat anti-mouse antibodies (A, C, and E). Cells transfected with myc-tagged Cdc42-Q61L alone were co-stained for F-actin (B). Cells cotransfected with either FLAG-tagged wild-type SPEC1 (D) or FLAG-tagged SPEC1-H38A (F) were processed for indirect immunofluorescence using a polyclonal FLAGTM/octaprobe antibody followed by FITC-labeled goat anti-rabbit secondary antibodies. The morphology of the COS1 cells transfected with Cdc42-Q61L resemble those cotransfected with the SPEC1-H38A mutant (compare A with E). Bar, 10 µm.

SPEC Expression Induces Non-apoptotic Blebbing in NIH-3T3 Fibroblasts-- Since SPEC1 expression did not noticeably alter the morphology of COS1 cells, we studied the effects of SPEC1 expression in NIH-3T3 fibroblasts. In NIH-3T3 fibroblasts, SPEC1 displayed a predominant cortical localization (Fig. 5A), and frequently, these transfected cells showed extensive membrane blebbing (Fig. 5A). F-actin stained strongly within the periphery of the blebs but not within the blebs (Fig. 5B). Expression of SPEC2 also showed the same cortical localization, membrane blebbing, and F-actin staining phenotype (Fig. 5, C and D). A similar pattern of cortical staining and blebbing were observed with a myc epitope tag located either at the N or C terminus of SPEC1 and using a 20-fold range of plasmid concentrations (100 ng to 2 µg; data not shown). Although this SPEC-induced membrane blebbing is morphologically similar to the membrane blebbing associated with apoptosis, there is no functional association of the SPEC-induced blebbing with apoptosis. That is, neither nuclear condensation following 4,6-diamidino-2-phenylindole staining of nuclei nor annexin-V positive staining, a marker for phosphotidylserine flipping in the membrane, was observed in these transfected cells (data not shown).


View larger version (110K):
[in this window]
[in a new window]
 
Fig. 5.   SPEC1 and SPEC2 induce membrane blebbing in NIH-3T3 fibroblasts. N-terminal FLAG epitope-tagged SPEC1 (A and B) or N-terminal FLAG epitope-tagged SPEC2 (C and D) constructs were transfected into NIH-3T3 fibroblasts. The cells were fixed 24 h after transfection and processed for indirect immunofluorescence using an anti-FLAG monoclonal antibody followed by FITC-conjugated goat anti-mouse secondary antibody to detect SPEC1(A) and SPEC2 (C) protein expression. Cells were co-stained for F-actin using Texas Red conjugated-phalloidin (B and D). Bar, 10 µm.

Quantitatively, membrane blebbing was observed in 40-60% of the FLAG epitope-tagged SPEC1 transfected cells but only in about 5% of cells expressing the vector-alone control (Fig. 6). We also used a bicistronic expression vector expressing both SPEC1 and EGFP from the same vector to rule out the possibility that the epitope tags might influence SPEC function. About 40% of the cells expressing the bicistronic SPEC1 construct showed a blebbing phenotype, whereas only 10% were blebbing with the EGFP-alone vector (Fig. 6). Taken together, these results demonstrate that expression of SPECs, whether epitope-tagged or untagged, leads to membrane blebbing in NIH-3T3 fibroblasts.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   Quantitative analysis of the effect of tagged and untagged SPEC1 on blebbing. NIH-3T3 fibroblasts were transfected, fixed, and processed for indirect immunofluorescence. NIH-3T3 fibroblasts showing at least two membrane blebs were scored as positive for blebbing as described under "Experimental Procedures"; values indicate mean and S.D. V, pCAF2 vector alone; SPEC1, pCAF2-SPEC1; EGFP, EGFP vector alone; SPEC1-EGFP, bicistronic SPEC1-EGFP vector.

SPEC1-induced Blebbing Is Independent of Cdc42 Activity-- To determine whether any of the three conserved regions in SPECs (see Fig. 1) are necessary for SPEC1-induced membrane blebbing, we examined the phenotype of cells transfected with various SPEC1 mutants. An additional N-terminal mutant, SPEC1-C10A,C11A was created within two conserved cysteine residues because of the potential role of these residues in lipid modification or protein interactions. Using cell counting it was found that both the positive and negative controls gave the expected results: approximately 44% of N-terminal FLAG-tagged SPEC1-transfected cells blebbed, as compared with only 4% using a vector-alone control (Fig. 7). The C-terminal double point mutant, SPEC1-Q62A,K66A, had no effect on the level of blebbing (Fig. 7). In contrast, the cells expressing the N-terminal mutant (SPEC1-C10A,C11A), which showed a similar level of expression and cortical localization, produced the blebbing phenotype in only 20% of the transfected cells (Fig. 7). Single or triple amino acid substitutions within the CRIB domain of SPEC1 resulted in somewhat fewer blebs, although they still produced significantly more than the negative controls (30% versus 4%; Fig. 7). Additional studies expressing a dominant negative mutant of Cdc42 (Cdc42-T17N) alone did not induce membrane blebbing, and co-expression with SPEC1 did not block membrane blebbing (data not shown). These results support a model whereby SPEC1-induced blebbing does not occur through classical Cdc42-effector interactions and suggest that SPEC1 may act independently of Cdc42 or perhaps upstream of Cdc42 to induce membrane blebbing. These data also confirm that SPEC-induced membrane changes are not directly due to sequestration of Cdc42.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Activity of different SPEC1 mutants in inducing membrane blebbing. Wild-type SPEC1 and different SPEC mutants were transfected into NIH-3T3 fibroblasts. At 24 h post-transfection, cells were fixed, processed for indirect immunofluorescence, and counted for blebbing as described above in the legend to Fig. 6; values indicate the mean and S.D. V, pCAF2 vector alone; SPEC1, pCAF2-SPEC1; C10A,C11A, pCAF2-SPEC1-C10A,C11A; H38A, pCAF2-SPEC1-H38A; Q62A,Q66A, pCAF2-SPEC1-Q62A,Q66A.

SPEC1 Expression Alters Cdc42-induced Changes in Cellular Morphology in NIH-3T3 Fibroblasts-- To more clearly define the relationship between Cdc42 activity and SPECs, we tested the effect of SPEC1/Cdc42 co-expression in NIH-3T3 fibroblasts. In these fibroblasts, expression of Cdc42L61 resulted in cells that predominantly exhibited a membrane ruffling phenotype, possibly through activation of Rac signaling. We then cotransfected SPEC1 or the SPEC1-CRIB mutants (SPEC1-H38A or SPEC1-P33A,H38A,H41A) with constitutively active Cdc42 and quantified by cell counting the number of transfected cells showing a ruffling phenotype. Expression of a constitutively active Cdc42 mutant (Cdc42-Q61L), but not wild type Cdc42 (data not shown), in NIH-3T3 fibroblasts induced marked membrane ruffling in 52% of the transfected cells (Fig. 8, A and B). Co-transfection of SPEC1 blocked ruffling in all but 5% of the transfected cells and increased the number of blebbing cells (Fig. 8, C and D). Coexpression of the SPEC-H38A mutant resulted in 34% of the cells showing a membrane ruffling phenotype (Fig. 8, E and F) and resembled cells transfected with Cdc42 alone (compare Fig. 8, A and B, with E and F). Similar results were also obtained with the SPEC1-P33A,H38A,H41A CRIB mutant (data not shown). It is also worthy to note that in these cotransfections experiments, SPEC1 and Cdc42 proteins appear to localize to similar regions within the cells, suggesting that SPECs and Cdc42 may be contained within the same signaling complexes (Fig. 8). As with COS1 cells, these transfections demonstrate that SPEC1 expression led to an altered Cdc42-induced morphology and that this alteration is dependent on the presence of an intact CRIB domain.


View larger version (87K):
[in this window]
[in a new window]
 
Fig. 8.   SPEC1 alters Cdc42-induced cell shape changes. NIH-3T3 fibroblasts were transfected with myc-tagged Cdc42-Q61L and processed for indirect immunofluorescence at 24 h post-transfection using monoclonal antibodies specific for the myc epitope tag followed by either Texas Red-conjugated goat anti-mouse antibodies or FITC-conjugated goat anti-mouse antibodies (A, C, and E). Cells transfected with myc-tagged Cdc42-Q61L alone were co-stained for F-actin (B). Cells cotransfected with either FLAG-tagged wild type SPEC1 (D) or FLAG-tagged SPEC1-H38A (F) were processed for indirect immunofluorescence using a polyclonal FLAGTM/octaprobe antibody followed by FITC-labeled goat anti-rabbit secondary antibodies. The morphology of the NIH-3T3 fibroblasts transfected with Cdc42-Q61L resemble those cotransfected with the SPEC1- CRIB mutant (compare A with E). Bar, 10 µm.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here we identify a new family of proteins capable of binding to Cdc42, designated SPECs, found in many eukaryotic species. The two human members, SPEC1 and SPEC2, are the smallest known GTPase-binding proteins. Their small size may explain why they were not detected in previous biochemical screens based on binding to Cdc42. Overexpression of different combinations of SPECs, SPEC mutants, and Cdc42 showed that SPEC expression inhibited Cdc42-induced JNK activity. SPEC overexpression also altered or reversed the cellular morphologies produced when Cdc42 is overexpressed in COS1 cells and in NIH-3T3 fibroblasts. The membrane blebbing induced by SPEC overexpression in NIH-3T3 fibroblasts was not observed in COS1 cells, possibly due to quantitative differences in expression levels of SPEC proteins between the two cell types. Nevertheless, these results show that SPECs are capable of modifying Cdc42-dependent signaling at both the biochemical and cellular levels in a CRIB-dependent manner. SPEC binding could prevent the interaction of Cdc42 with other effector proteins. Consistent with this model, a polypeptide containing just the CRIB domain of PAK can effectively inhibit Cdc42 activation of JNK kinase (34) and block transcriptional activation (35), whereas a polypeptide containing the CRIB domain of ACK-1 can act as a Cdc42-specific inhibitor, blocking v-Ha-Ras-induced transformation (36).

However, we do not know if the specific biochemical and biological effects observed here with overexpressed SPECs reflect the normal function of these small proteins. In particular, SPEC overexpression induced membrane blebbing in NIH-3T3 fibroblast that was not blocked by dominant negative Cdc42 expression. Despite these findings, it is still possible that SPECs function in Cdc42-induced morphological changes, since a dominant negative approach may not rescue the abnormal morphology of overexpressed SPEC protein. Furthermore, various studies have shown that non-apoptotic membrane blebs function normally in cell spreading (37, 38) and locomotion (39-41). Mechanistically, membrane blebs occur at sites where the cortical actin is locally depolymerized or detached from the membrane (38, 40, 41) via alteration in cortical actin-binding proteins (40), myosin light chain kinase activity (42, 43), and/or focal complex assembly (43). Thus, it is tempting to speculate that SPECs may function as classical Cdc42 effector proteins by altering the normal signaling pathways leading to actin, myosin, and/or focal complex assembly.

The existence of small proteins that bind important signaling molecules is not unique to Cdc42. Recently, an 18-kDa protein, A-kinase anchoring protein-18 (AKAP18), was found to function as a scaffold protein, coupling protein kinase A signaling to calcium and sodium channels (44-46). Interestingly, AKAP18 and SPECs share many structural and functional similarities. First, both are small proteins: AKAP18, SPEC1, and SPEC2 are 81, 79, and 84 amino acids long, respectively. Second, both bind their ligands, protein kinase A or Cdc42, through their central binding regions. Third, both localize to the plasma membrane. Although the membrane localization of AKAP18 involves lipid modification of the N terminus, we have not yet identified the region required to target SPECs to the membrane in NIH-3T3 fibroblasts. Based on these similarities, we speculate that SPECs, like AKAP18, may function as scaffolding molecules to recruit other signaling proteins to Cdc42 complexes. Future studies are aimed at identifying such SPEC-binding partners.

    FOOTNOTES

* This work was supported by Susan G. Komen Foundation Grant 9851 (to P. D. B.) and a Department of Defense (DOD) breast cancer pre-doctoral fellowship (to D. M. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF187845 and AF189692.

To whom correspondence should be addressed: Rm. EG16, New Research Bldg., Lombardi Cancer Center 3970 Reservoir Rd. NW, Georgetown University Medical Center, Washington, D. C. 20007. Tel.: 202-687-1444; Fax: 202-687-7505; E-mail: burbelpd@gunet.georgetown.edu.

Published, JBC Papers in Press, May 16, 2000, DOI 10.1074/jbc.M002832200

    ABBREVIATIONS

The abbreviations used are: CRIB, Cdc42/Rac interactive binding domain; AKAP, A-kinase anchoring protein; EST, expressed sequence tag; JNK, c-Jun N terminal kinase; SPEC, small protein effector of Cdc42; EGFP, enhanced green fluorescent protein; PCR, polymerase chain reaction; FITC, fluorescein isothiocyanate; contig, group of overlapping clones; HA, hemagglutinin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kroschewski, R, Hall, A, and Mellman, I. (1999) Nat. Cell Biol. 1, 8-13
2. Drechsel, D. N., Hyman, A. A, Hall, A, and Glotzer, M. (1997) Curr. Biol. 7, 12-23
3. Johnson, D. I. (1999) Microbiol. Mol. Biol. Rev. 63, 54-105
4. Kozma, R., Ahmed, S., Best, A., and Lim, L. (1995) Mol. Cell. Biol. 15, 1942-1952
5. Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62
6. Stossel, T. P. (1993) Science 260, 1086-1094
7. Burbelo, P., Drechsel, D., and Hall, A. (1995) J. Biol. Chem. 270, 29071-29074
8. Hart, M. J., Callow, M. G., Souza, B., and Polakis, P. (1996) EMBO J. 15, 2997-3005
9. Kuroda, S., Fukata, M., Kobayashi, K., Nakafuku, M., Nomura, N., Iwamatsu, A., and Kaibuchi, K. (1996) J. Biol. Chem. 271, 23363-23367
10. Manser, E., Leung, T., Salihuddin, H., Zhao, Z., and Lim, L. (1994) Nature 367, 40-46
11. Martin, G. A., Bollag, G., McCormick, F., and Abo, A. (1995) EMBO J. 14, 1970-1978
12. Leung, T., Chen, X., Tan, I., Manser, E., and Lim, L. (1998) Mol. Cell. Biol. 18, 130-140
13. Manser, E., Leung, T., Salihuddin, H., Tan, L., and Lim, L. (1993) Nature 363, 364-367
14. Teramoto, H., Coso, O. A., Miyata, H., Igishi, T., Miki, T., and Gutkind, J. S. (1996) J. Biol. Chem. 271, 27225-27228
15. Symons, M., Derry, J. M., Karlak, B., Jiang, S., Lemahieu, V., McCormick, F., Francke, U., and Abo, A. (1996) Cell 84, 723-734
16. Miki, H., Sasaki, T., Takai, Y., and Takenawa, T. (1998) Nature 391, 93-96
17. Burbelo, P. D., Snow, D. M., Bahou, W., and Spiegel, S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9083-9088
18. Joberty, G., Perlungher, R. R., and Macara, I. G. (1999) Mol. Cell. Biol. 19, 6585-6597
19. Sells, M. A., Boyd, J. J., and Chernoff, J. (1999) J. Cell Biol. 145, 837-849
20. Bagrodia, S., Derijard, B., Davis, R. J., and Cerione, R. A. (1995) J. Biol. Chem. 270, 27995-27998
21. Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., and Bokoch, G. M. (1995) J. Biol. Chem. 270, 23934-23936
22. Brown, J. L., Stowers, L., Baer, M., Trejo, J., Coughlin, S., and Chant, J. (1996) Curr. Biol. 6, 598-605
23. Rudel, T., and Bokoch, G. M. (1997) Science 276, 1571-1574
24. Yang, W., Lin, Q., Guan, J. L., and Cerione, R. A. (1999) J. Biol. Chem. 274, 8524-8530
25. Tibbles, L. A., Ing, Y. L., Keifer, F., Chan, J., Iscove, N., Woodgett, J. R., and Lassam, N. J. (1996) EMBO J. 15, 7026-7035
26. Nagata, K., Puls, A., Futter, C., Aspenstrom, P., Schaefer, E., Nakata, T., Hirokawa, N., and Hall, A. (1998) EMBO J. 17, 149-158
27. Suetsugu, S., Miki, H., and Takenawa, T. (1998) EMBO J. 17, 6516-6526
28. Machesky, L. M., and Insall, R. H. (1998) Curr. Biol. 8, 1347-1356
29. Rohatgi, R., Ma, L., Miki, H., Lopez, M., Kirchhausen, T., Takenawa, T., and Kirschner, M. W. (1999) Cell 97, 221-231
30. Aspenstrom, P., Lindberg, U., and Hall, A. (1996) Curr. Biol. 6, 70-75
31. Coso, O. A., Chiariello, M., Yu, J. C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) Cell 81, 1137-1146
32. Abdul-Manan, N., Aghazadeh, B., Liu, G. A., Majumdar, A., Ouerfelli, O., Siminovitch, K. A., and Rosen, M. K. (1999) Nature 399, 379-383
33. Mott, H. R., Owen, D., Nietlispach, D., Lowe, P. N., Manser, E., Lim, L., and Laue, E. D. (1999) Nature 399, 384-388
34. Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157
35. Osada, S., Izawa, M., Koyama, T., Hirai, S., and Ohno, S. (1997) FEBS Lett. 404, 227-233
36. Nur-E-Kamal, M., Kamal, J., Qureshi, M., and Maruta, H. (1999) Oncogene 18, 7787-7793
37. Erickson, C. A., and Trinkaus, J. P. (1976) Exp. Cell Res. 99, 375-384
38. Cunnignham, C. C. (1995) J. Cell Biol. 129, 1589-1599
39. Trinkaus, J. P. (1980) Prog. Clin. Biol. Res. 41, 887-906
40. Keller, H., and Eggli, P. (1998) Cell Motil. Cytoskeleton 41, 181-193
41. Cunningham, C. C., Gorlin, J. B., Kwiatkowski, D. J., Hartwig, J. H., Janmey, P. A., Byers, H. R., and Stossel, T. P. (1992) Science 255, 325-327
42. Mills, J. C., Stone, N. L., Erhardt, J., and Pittman, R. N. (1998) J. Cell Biol. 140, 627-636
43. Huot, J., Houle, F., Rousseau, S., Deschesnes, R. G., Shah, G. M., and Landry, J. (1998) J. Cell Biol. 143, 1361-1373
44. Fraser, I. D., Tavalin, S. J., Lester, L. B., Langeberg, L. K., Westphal, A. M., Dean, R. A., Marrion, N. V., and Scott, J. D. (1998) EMBO J. 17, 2261-2272
45. Gray, P. C., Tibbs, V. C., Catterall, W. A., and Murphy, B. J. (1997) J. Biol. Chem. 272, 6297-6302
46. Tibbs, V. C., Gray, P. C., Catterall, W. A., and Murphy, B. J. (1998) J. Biol. Chem. 273, 25783-25788


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Med. Genet.Home page
X-j Luo, H-b Diao, J-k Wang, H Zhang, Z-m Zhao, and B Su
Association of haplotypes spanning PDZ-GEF2, LOC728637 and ACSL6 with schizophrenia in Han Chinese
J. Med. Genet., December 1, 2008; 45(12): 818 - 826.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Nilsson, P. Eden, E. Olsson, R. Mansson, I. Astrand-Grundstrom, B. Strombeck, K. Theilgaard-Monch, K. Anderson, R. Hast, E. Hellstrom-Lindberg, et al.
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes
Blood, October 15, 2007; 110(8): 3005 - 3014.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. M. Navratil, J. G. Knoll, J. D. Whitesell, S. A. Tobet, and C. M. Clay
Neuroendocrine Plasticity in the Anterior Pituitary: Gonadotropin-Releasing Hormone-Mediated Movement in Vitro and in Vivo
Endocrinology, April 1, 2007; 148(4): 1736 - 1744.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. P. Giacomini, S. Y. Leung, X. Chen, S. T. Yuen, Y. H. Kim, E. Bair, and J. R. Pollack
A Gene Expression Signature of Genetic Instability in Colon Cancer
Cancer Res., October 15, 2005; 65(20): 9200 - 9205.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. H. Ching, A. E. Kisailus, and P. D. Burbelo
The Role of SPECs, Small Cdc42-binding Proteins, in F-actin Accumulation at the Immunological Synapse
J. Biol. Chem., June 24, 2005; 280(25): 23660 - 23667.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
M. de Toledo, F. Senic-Matuglia, J. Salamero, G. Uze, F. Comunale, P. Fort, and A. Blangy
The GTP/GDP Cycling of Rho GTPase TCL Is an Essential Regulator of the Early Endocytic Pathway
Mol. Biol. Cell, December 1, 2003; 14(12): 4846 - 4856.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. W. Peck, M. Oberst, K. B. Bouker, E. Bowden, and P. D. Burbelo
The RhoA-binding protein, Rhophilin-2, Regulates Actin Cytoskeleton Organization
J. Biol. Chem., November 8, 2002; 277(46): 43924 - 43932.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
I. G. Serebriiskii, O. Mitina, E. N. Pugacheva, E. Benevolenskaya, E. Kotova, G. G. Toby, V. Khazak, W. G. Kaelin, J. Chernoff, and E. A. Golemis
Detection of Peptides, Proteins, and Drugs That Selectively Interact With Protein Targets
Genome Res., November 1, 2002; 12(11): 1785 - 1791.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. S. Gladfelter, J. J. Moskow, T. R. Zyla, and D. J. Lew
Isolation and Characterization of Effector-Loop Mutants of CDC42 in Yeast
Mol. Biol. Cell, May 1, 2001; 12(5): 1239 - 1255.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. S. Hirsch, D. M. Pirone, and P. D. Burbelo
A New Family of Cdc42 Effector Proteins, CEPs, Function in Fibroblast and Epithelial Cell Shape Changes
J. Biol. Chem., January 5, 2001; 276(2): 875 - 883.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Richnau and P. Aspenstrom
RICH, a Rho GTPase-activating Protein Domain-containing Protein Involved in Signaling by Cdc42 and Rac1
J. Biol. Chem., September 7, 2001; 276(37): 35060 - 35070.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. K. Reeder, I. G. Serebriiskii, E. A. Golemis, and J. Chernoff
Analysis of Small GTPase Signaling Pathways Using p21-activated Kinase Mutants That Selectively Couple to Cdc42
J. Biol. Chem., October 26, 2001; 276(44): 40606 - 40613.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/30/22650    most recent
M002832200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow